Research of Mitomycin-C saturation in dacryocystorhinostomy osteotomy site tissue
- Authors: At´kova E.L.1, Root A.O.1, Krahoveckiy N.N.1, Yartsev V.D.1, Yartsev S.D.2
-
Affiliations:
- Scientific Research Institute of Eye Diseases
- A.N. Frumkin Institute of physical chemistry and electrochemistry, RAS
- Issue: Vol 10, No 1 (2017)
- Pages: 17-22
- Section: Articles
- URL: https://journals.rcsi.science/ov/article/view/6312
- DOI: https://doi.org/10.17816/OV10117-22
- ID: 6312
Cite item
Abstract
Introduction. Mitomycin-C is an alkylating antibiotic used to prevent excessive scar formation in the dacryostoma area after dacryocystorhinostomy. In vitro studies proved its inhibition effect on fibroblast growth in 0.2 mg/ml concentration. Up to date, clinical data on its efficacy remain contradictory.
Aim. To evaluate the concentration of Mitomycin-C in nasal cavity and lacrimal sac mucosa after topical application and to determine the clinical efficacy of this procedure.
Materials and methods. 30 patients with nasolacrimal duct obliteration underwent an endonasal endoscopic dacryocystorhinostomy. At the end of the surgery, at the osteotomy site, a sponge soaked in Mitomycin-C 0,2 mg/ml was applied for 3 minutes. Nasal mucosa biopsy was performed immediately after application, in 30 minutes, and at the 1st day after surgery. Biopsy material analysis of was performed by liquid chromatography – mass spectrometry. The surgical treatment efficacy was established according to proposed efficacy criteria.
Results. The analysis of Mitomicyn-C concentrations established them to be: 626 ± 176 ng/g tissue immediately after application, 230 ± 61 ng/g tissue in 30 minutes after application. In 24 hours after surgery, there was no Mitomycin-C in the tissue. Surgical efficacy was 86.7%, recurrences were found in 13.3% of cases.
Conclusion. Surgery clinical results coincide with those obtained by other researchers. But chemical investigation showed that Mitomycin-C tissue concentration was lower than that in previous in vitro studies.
Full Text
##article.viewOnOriginalSite##About the authors
Evgeniya L. At´kova
Scientific Research Institute of Eye Diseases
Author for correspondence.
Email: evg.atkova@mail.ru
PhD, head of the Department of Pathology of the lacrimal apparatus
Russian Federation, MoscowAnna O. Root
Scientific Research Institute of Eye Diseases
Email: a.root@niigb.ru
MD, postgraduate student
Russian Federation, MoscowNikolay N. Krahoveckiy
Scientific Research Institute of Eye Diseases
Email: krahovetskiynn@mail.ru
MD, researcher, Department of Pathology of the lacrimal apparatus
Russian Federation, MoscowVasiliy D. Yartsev
Scientific Research Institute of Eye Diseases
Email: yartsew@ya.ru
MD, researcher, Department of Pathology of the lacrimal apparatus
Russian Federation, MoscowStepan D. Yartsev
A.N. Frumkin Institute of physical chemistry and electrochemistry, RAS
Email: yartsew1@yandex.ru
postgraduate student
Russian Federation, MoscowReferences
- Hata T, Hoshi T, Kanamori K, et al. Mitomycin, a new antibiotic from Streptomyces. I J Antibiot (Tokyo). 1956 Jul;9(4):141-6.
- Hu D, Sires B, Tong D, et al. Effect of brief exposure to mitomycin C on cultured human nasal mucosa fibroblasts. Ophthal Plast Reconstr Surg. 2000;16(2):119-125. doi: 10.1097/00002341-200003000-00006.
- Ugurbas SH, Zilelioglu G, Sargon MF, et al. Histopathologic effects of mitomycin-C on endoscopic transnasal dacryocystorhinostomy. Ophthalmic Surg Lasers. 1997;28:300-4.
- Selig YK, Biesman BS, Rebeiz EE. Topical application of mitomycin-C in endoscopic dacryocystorhinostomy. Am J Rhinol. 2000May-Jun;14(3):205-7. doi: 10.2500/105065800782102672.
- Zilelioğlu G, Uğurbaş S, Anadolu Y, et al. Adjunctive use of mitomycin C on endoscopic lacrimal surgery. Br J Ophthalmol. 1998;82(1):63-66. doi: 10.1136/bjo.82.1.63.
- Dolmetsch A. Nonlaser endoscopic endonasal dacryocystorhinostomy with adjunctive mitomycin C in nasolacrimal duct obstruction in adults. Ophthalmology. 2010;117:1037-1040. doi: 10.1016/j.ophtha.2009.09.028.
- Ozkiriş M, Ozkiriş A, Göktaş S. Effect of mitomycin C on revision endoscopic dacryocystorhinostomy. J Craniofac Surg. 2012;23(6):608-10. doi: 10.1097/scs.0b013e31826c7cf7.
- Ghosh S, Roychoudhury A, Roychaudhuri BK. Use of mitomycin C in endo-DCR. Indian J Otolaryngol Head Neck Surg. 2006 Oct;58(4):368-9. doi: 10.1007/BF03049597.
- Белоглазов В.Г., Груша О.В., Саад-Ельдин Н.М., и др. Профилактика и лечение рецидивов после дакриоцисториностомии // Вестник офтальмологии. – 1999. – № 5. – С. 14–17. [Beloglazov VG, Grusha OV, Saad-El’din NM, et al. Profilaktika i lechenie retsidivov posle dakriotsistorinostomii. Vestnik oftal’mologii. 1999;5:14-17. (In Russ.)]
- Ragab S, Elsherif H, Shehata E, et al. Mitomycin C-enhanced revision endoscopic dacryocystorhinostomy: a prospective randomized controlled trial. Otolaryngol Head Neck Surg. 2012;147(5):937-942. doi: 10.1177/0194599812450280.
- Apuhan T, Yildirim Y, Eroglu F, Sipahier A. Effect of mitomycin C on endoscopic dacryocystorhinostomy. J Craniofac Surg. 2011;22(6):2057-2059. doi: 10.1097/SCS.0b013e3182319863.
- Ali MJ, Mariappan I, Maddileti S, et al. Mitomycin C in dacryocystorhinostomy: the search for the right concentration and duration – a fundamental study on human nasal mucosa fibroblasts. Ophthal Plast Reconstr Surg. 2013Nov-Dec;29(6):469-74. doi: 10.1097/IOP.0b013e3182a23086.
- Ali MJ, Baig F, Lakshman M, Naik MN. Electron microscopic features of nasal mucosa treated with topical mitomycin C: implications in dacryocystorhinostomy. Ophthal Plast Reconstr Surg. 2015 Mar-Apr;31(2):103-7. doi: 10.1097/IOP.0000000000000205.
- Атькова Е.Л., Краховецкий Н.Н., Ярцев В.Д., Роот А.О. Эффективность применения препарата «Мезогель» при эндоскопической эндоназальной дакриоцисториностомии // Точка зрения. Восток-Запад. – 2015. – № 1. – С. 222–224. [At’kova EL, Krakhovetskiy NN, Yartsev VD, Root AO. Effektivnost’ primeneniya preparata “Mezogel’” pri endoskopicheskoy endonazal’noy dakriotsistorinostomii. Tochka zreniya. Vostok-Zapad. 2015;(1):222-224. (In Russ.)]